Diagnosis of Hypoaldosteronism in Infancy by Vlachopapadopoulou, Elpis-Athina & Bonataki, Myrto
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books











Hypoaldosteronism is associated with either insufficient aldosterone 
 production or lack of responsiveness to aldosterone and can be isolated or in 
the context of primary adrenal failure. Τhe severity of clinical manifestations is 
inversely correlated to age, with the neonatal period being the most vulnerable 
time for a patient to present with mineralocorticoid insufficiency. Salt-wasting 
forms of congenital adrenal hyperplasia (CAH), adrenal hypoplasia congenita 
(AHC), aldosterone synthase deficiency (ASD) and pseudohypoaldosteronism 
(PHA) are all causes of hypoaldosteronism in infancy. Affected infants present 
with salt wasting, failure to thrive and potentially fatal hyperkalemia and shock. Α 
blood sample for the essential hormonal investigations should be collected before 
any steroid treatment is given, in order to confirm aldosterone insufficiency and 
to determine the underlying cause. Renal ultrasonography and urine culture are 
also useful for exclusion of secondary causes of aldosterone resistance. Initial 
management requires treatment of electrolyte imbalances and restoration of 
intravascular fluid volume. In case of a salt-wasting crisis, affected infants are 
usually treated initially with both hydrocortisone and fludrocortisone, pending 
the results of investigations. Interpretation of the hormonal profile will guide 
further therapy and molecular analysis of candidate genes.
Keywords: hypoaldosteronism, salt-wasting crisis, hyponatremia, hyperkalemia, 
pseudohypoaldosteronism
1. Introduction
Aldosterone, the most important mineralocorticoid, regulates electrolyte 
balance and intravascular volume by controlling renal sodium reabsorption and 
potassium excretion. Hypoaldosteronism is a rare, but potentially severe condi-
tion, associated with hyponatremia, hyperkalemia, metabolic acidosis and volume 
depletion. Given the higher mineralocorticoid demand during the critical neonatal 
period, the clinical presentation of aldosterone insufficiency in this age group can 
be dramatic [1–3].
2. The renin-angiotensin-aldosterone system in infancy
Regulation of fetal salt and water balance is handled by the placenta, so 
newborns with aldosterone defects have a normal electrolyte profile at birth. 
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Postnatally, healthy term neonates display a state of functional hypoaldosteronism 
(lower sodium and higher potassium concentrations), that contrasts with mark-
edly increased aldosterone and renin secretion rates [2–5]. Indeed, it has been 
reported, that neonates have a mean plasma aldosterone level of 80 ng/dl versus 
16.6 ng/dl for adults. Similarly, plasma renin activity (PRA) is severalfold higher 
in the first 3 months of life, than the levels reported later in adult life (450 and 
25 ng liter−1 min−1 respectively) [6]. Concurrent partial aldosterone resistance is 
attributed to the low mineralocorticoid receptor (MR) expression and the weak 
11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) activity of the neonatal 
kidney. Aldosterone unresponsiveness may, at least in part, account for the extra-
cellular fluid compartment contraction and weight loss during the first days of 
life [7–9].
3. Clinical presentation of hypoaldosteronism
Biochemically, hypoaldosteronism is characterized by hyponatremia, hyperka-
lemia, prerenal azotemia and non-anion gap metabolic acidosis (hyperkalemic or 
type 4 renal tubular acidosis). Τhe severity of clinical manifestations is inversely 
correlated to age, due to changes in adrenal and renal physiology [10, 11].
The critical neonatal period is clearly the most vulnerable time for an affected 
person to present with hypoaldosteronism [3]. Babies with mineralocorticoid insuf-
ficiency start to lose whole body sodium and water from day 1 in their urine. Overt 
electrolyte disturbances usually develop after the 4th day of life in infants with salt-
wasting 21-hydroxylase deficiency, but a very early onset of symptoms may be seen 
in cases of severe systemic PHA. Affected infants eventually present with dehydra-
tion, vomiting and failure to thrive, while urine output remains excessively high for 
the degree of dehydration [6, 10]. Early warning signs, such as failure to reach birth 
weight by two weeks of age or excessive weight loss (greater than 10–12%) during 
the first days of life, should always prompt a careful assessment of hydration status, 
kidney function and electrolyte profile [7].
Clinical manifestations associated with hyponatremia are primarily neurologic, 
due to osmotic water shift intracellularly, parenchymal edema and brain ischemia. 
Frequent symptoms include vomiting, poor feeding and lethargy or irritability. 
Pronounced symptoms, such as seizures, are encountered rarely due to the insidi-
ous onset (>48 h) of hyponatremia. Open sutures and fontanelles in neonates, also 
act as a protective mechanism preventing intracranial hypertension [12, 13]. Yet 
infants with hypoaldosteronism are at risk of acute deterioration and might present 
in circulatory collapse with lethargy, tachycardia, hyperpnea, prolonged capillary 
refill, and cool and mottled extremities. Hypotension, a very late dehydration sign, 
occurs when all compensatory mechanisms to maintain organ perfusion have failed 
[14]. Hyperkalemia is clinically manifested by muscular weakness and cardiac 
disturbances (bradycardia, ventricular fibrillation, hypotension or cardiac arrest). 
Electrocardiogram (ECG) signs of hyperkalemia include repolarization abnormali-
ties, peaked T-waves, QRS widening and depression of ST-segment. Arrhythmias 
may appear at any time and can lead to sudden death [15, 16].
Hypoaldosteronism has a much milder course in older children and adults, as 
aldosterone requirements normally decrease with age. Children with aldosterone 
insufficiency may present with subtle symptoms, such as postural hypotension and 
salt craving or even with asymptomatic growth failure. Autonomous addition of salt 
in the diet can delay or mask the presentation, until a simple viral gastroenteritis 
or a hot day associated with excessive sweating triggers the cascade of clinical 
 manifestations [10, 11].
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Reversible growth impairment is a well-known feature of several conditions 
accompanied by acidosis or electrolyte derangement (e.g., Bartter’s syndrome or 
renal tubular acidosis) [6]. Accordingly, children with aldosterone insufficiency 
may present with linear growth deceleration due to chronic hyponatremia and 
acidosis. Sodium is an important growth factor, stimulating cell prolifera-
tion, protein synthesis and increasing cell mass. The mechanism whereby Na+ 
promotes growth is through alkalinization of the cell interior, via a sodium-
dependent Na+/H+-antiporter. Sodium depletion and acidosis lead to decreased 
antiporter system’s activity and despite adequate macronutrient intake, children 
fail to thrive [17, 18].
4. Diagnostic workup
Hypoaldosteronism should be considered in any infant with persistent hyper-
kalemia and hyponatremia if there is no apparent cause, such as renal failure or 
prematurity. A diagnostic algorithm for infants presenting with salt-wasting and 
hyperkalemia (suspected mineralocorticoid defect) is presented in Figure 1 [8, 16].
Renal function must be evaluated carefully, since renal excretion of potassium 
is directly dependent upon glomerular filtration rate (GFR). Renal adaptive mecha-
nisms allow the kidneys to maintain potassium homeostasis until the GFR decreases 
to less than 15 ml/min/1.73 m2 [16, 19].
Hyperkalemia and hyponatremia are well-recognized complications of pre-
maturity. Hyperkalemia may be observed, even in the absence of oliguria, in very 
low birth weight preterm infants weighing less than 1,000 g. The serum potassium 
concentration may be as high as 9.0 mEq/1 and be accompanied by significant 
ECG irregularities [15]. Plasma potassium concentration decreases gradually from 
6.5 ± 0.5 mEq/1 at 30— 32 weeks to 5.1 ± 0.2 mEq/1 at 39–41 weeks. Premature 
infants of <36 weeks gestational age (GA) are also unable to conserve sodium. The 
more immature the infant, the greater the risk and the degree of hyponatremia [20]. 
Urinary sodium excretion is 3.1 ± 0.5 mEq/kg/day (mean ± SE) in the newborn of 
30–32 weeks gestational age and 1.2 ± 0.4 mEq/kg/day at 36—38 weeks gestational 
age [21].
The clinical scenario of a dehydrated infant with salt wasting and hyperkalemia 
represents a medical emergency implying inadequate mineralocorticoid action 
or complete adrenal insufficiency (both glucocorticoid and mineralocorticoid 
deficiency). The most common diagnosis in neonates is CAH due to 21-hydroxylase 
deficiency. Other conditions to be considered in infancy are the rare salt-wasting 
forms of CAH adrenal hypoplasia congenita, aldosterone synthase deficiency, PHA 
and drug effects [7, 22, 23].
Considerable overlap exists in the clinical and biochemical presentation of most of 
the above-mentioned endocrine diseases and only a few clinical signs can help clini-
cians to differentiate between them [23, 24]. A careful examination of the external 
genitalia is indicated in all infants with hyponatremia and hyperkalemia and might 
reveal valuable information towards the appropriate diagnosis [25]. 46, XX infants 
with 21-hydroxylase deficiency exhibit variable extent of virilization due to excessive 
androgen production. On the contrary, signs of undervirilization such as hypospadias 
are noted in 46,XY infants with 3β-hydroxysteroid dehydrogenase deficiency due 
to decreased androgen production. Infant boys with 21-hydroxylase deficiency have 
normal external genitalia or subtle penile enlargement that can be easily overlooked 
[25–29]. Impaired cortisol secretion is suggested clinically by low glucose levels and 
vascular tone insufficiency (hypotension) that is unresponsive to initial resuscitation. 
Last, although not always clinically obvious, increased pigmentation is a distinguishing 
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feature of primary adrenal insufficiency (PAI) associated with high levels of melano-
cyte-stimulating hormone (MSH), a ligand derived from pro-opiomelanocortin that 
causes hyperpigmentation of melanin-containing skin cells [6, 28].
The following investigations are suggested as a first - line diagnostic workup in 
infants with apparent mineralocorticoid deficiency:
• A critical sample for ACTH determination, cortisol, 17-hydroprogesterone  
(17- OHP), Δ4 - androstenedione, aldosterone levels and renin level or PRA 
should be drawn before administration of hydrocortisone.
Figure 1. 
Diagnostic approach to infants presenting with hyponatremia, hyperkalemia from references [8, 16] 
(GFR: glomerular filtration rate, PRA: plasma renin activity, 17OHP: 17-hydroxyprogesterone, Δ4-Α: 
Δ4-androstenedione, Aldo: aldosterone, CAH: congenital adrenal hyperplasia, AHC: adrenal hypoplasia 
congenita, PHA: pseudohypoaldosteronism, sPHA: systemic PHA, rPHA: renal PHA, ΑSD: aldosterone 
synthase deficiency, UTI: urinary tract infection).
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• A urine collection by suprapubic aspiration or catheterization for microscopic 
analysis, urine culture and urine electrolytes measurement.
• Abdominal ultrasonography [7, 10].
Hypoaldosteronism may be challenging to diagnose promptly, because aldo-
sterone and renin assays are generally sent to a reference laboratory and results are 
usually delayed. Thus, urinary electrolyte assessment and abdominal ultrasonogra-
phy are useful adjuncts in a clinical setting [12, 30].
4.1 Urine electrolytes
Urine sodium is expected to be low (usually <25) in hyponatremia, when the 
renal response is intact. A urine sodium concentration greater than 25 mEq/L 
demonstrates inappropriately high sodium excretion in the hyponatremic infant, 
suggesting aldosterone deficiency or resistance. Nevertheless, we should keep in 
mind that urinary sodium losses may not be excessive if the infant is salt depleted 
[12, 30, 31].
In addition to measuring urinary sodium, it is useful to estimate potassium 
excretion. The preferred method to estimate potassium excretion by the distal 
tubule is the transtubular potassium (K) concentration gradient (TTKG):
 ( ) ( )TTKG Blood Osmolality Urine K / Blood K Urine Osmolality= ∗ ∗  
TTKG is expected to be high (>10) during hyperkalemia, as a result of appropri-
ate aldosterone activity. TTKG values of less than six indicate impaired aldosterone 
action in the distal nephron as the cause of the hyperkalemia [31, 32]. Calculating 
TTKG before and after fludrocortisone administration is also useful in distinguish-
ing patients who have mineralocorticoid deficiency versus resistance. An increase 
in TTKG values is observed after administering fludrocortisone in aldosterone-
deficient states, but no change is seen in the case of aldosterone resistance [16].
4.2 Abdominal ultrasonography
Abdominal ultrasonography is a rapid, sensitive and non-invasive test that 
can provide valuable diagnostic information. The diagnosis of CAH is supported 
when a combination of 2 or more of the three following abnormalities are evident 
in adrenal sonography: (a) increased size (limb width > 4 mm), (b) lobulated or 
cerebriform surface and c) abnormal echogenicity. Adrenal imaging can also detect 
physical causes of adrenal insufficiency such as hemorrhage [33, 34].
Pelvic ultrasonography is indicated to evaluate internal genitourinary anatomy 
in infants with a suspected defect in steroidogenesis. Ultrasonography might reveal 
the presence of Müllerian structures in severely virilized infants with 21-hydroxy-
lase deficiency carrying a 46,XX karyotype [35]. Accordingly, the lack of Müllerian 
structures in an infant with a salt-wasting crisis and female appearing external 
genitalia is found in 46,XY infants with classic congenital lipoid adrenal hyperplasia 
(CLAH) [36].
Urine culture and renal ultrasonography may allow early recognition of second-
ary PHA in infants with salt-wasting by detecting renal malformations and urinary 
tract infection (UTI). Further imaging with voiding cystourethrography (VCUG) 
and 99mTc-mercaptoacetyltriglycine (MAG3) scintigraphy may demonstrate 
vesicoureteral reflux (VUR) or obstruction [37].
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4.3 Adrenal function tests
Evaluating apparent mineralocorticoid deficiency and eliciting the correct diag-
nosis requires a careful interpretation of adrenal function tests. Hypoaldosteronism 
can be isolated or in the context of PAI and concurrent cortisol production failure 
[38]. Serum cortisol level is expected to be elevated in the hypovolemic, acidotic 
patient with a functioning adrenal gland [39]. Diagnosis of PAI is suggested by an 
elevated plasma corticotropin (ACTH) concentration (frequently >100 pg/mL) 
in the presence of a low serum cortisol concentration (usually <10 mg/dL) [40]. 
Samples in young infants may be obtained at random, because diurnal secretion 
of ACTH and cortisol is not yet established, while by 6 months of age and beyond 
samples should be collected close to 8 AM [41]. In the setting of diagnostic uncer-
tainty, confirmation of the diagnosis is established by an ACTH-stimulation test 
(250 μg for children >2 years, 15 μg/kg for infants and 125 μg for children <2 years, 
intravenously). A subnormal peak cortisol level (<18 μg/dL) 30 or 60 minutes after 
ACTH administration is diagnostic of PAI [28, 29].
1. In case of hypocortisolism the first step is to evaluate 17-OHP level, because 
21-hydroxylase deficiency is the most common cause of PAI in neonates and 
young infants. Most affected infants have concentrations greater than 35 ng/L 
and all have concentrations greater than 10 ng/L. If 17-OHP levels are normal, 
other adrenal insufficiency causes need to be considered. Once 21-hydroxylase 
deficiency has been ruled out, the most frequent cause of adrenal insufficiency 
in male neonates are the DAX-1 mutations. Other causes include rare non- 
virilizing forms of salt-wasting CAH and neonatal adrenal hemorrhage. Adrenal 
hemorrhage should be suspected in the newborn presenting with adrenal 
insufficiency and hypovolemic shock in the first week of life and diagnosis is 
confirmed by abdominal sonography [34]. Screening for possible autoimmune 
adrenalitis with adrenal autoantibodies and for X-linked adrenoleukodystro-
phy (ALD) with very long-chain fatty acids (VLCFA) is indicated in infants 
presenting at an age older than 6 months [10, 42].
2. Normal cortisol, ACTH and 17-OHP levels are consistent with isolated hypoal-
dosteronism without parallel cortisol deficiency. The next step is to evaluate 
the renin and aldosterone levels. Elevated PRA and low aldosterone values, 
particularly an elevated PRA ratio to aldosterone are markers of primary 
( hyperreninemic) hypoaldosteronism [26]. Low aldosterone and renin con-
centrations are consistent with hyporeninemic hypoaldosteronism, a diagnosis 
that is rarely seen in infants. Last, the diagnosis of PHA is established when 
high aldosterone and renin concentrations are evident in the face of salt wast-
ing and hyperkalemia. In such cases, a renal etiology should be sought as a 
cause of secondary PHA. Urine culture and renal ultrasonography should be 
performed in any infant with electrolyte disturbances to exclude infection and 
obstructive uropathy, even in the absence of fever or other  symptoms and signs 
of pyelonephritis [43].
Antenatal Bartter syndrome should be included in the differential diagnosis 
of a neonate presenting with hyperkalemia, hyponatremia and hyperreninemic 
hyperaldosteronism. In general, Bartter syndrome is a group of inherited tubular 
disorders, characterized renal salt wasting, hypokalemia, metabolic alkalosis and 
normotensive hyperreninemic hyperaldosteronism. Interestingly, the initial clinical 
presentation of type II antenatal Bartter syndrome is an important mimic of type 1 
PHA. Transient neonatal hyperkalemia, occasionally severe, is observed within the 
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first three weeks of life in the majority of patients, obscuring the initial diagnosis, 
until the infant becomes hypokalemic. A mean peak plasma potassium level of 
9.0 mmol/L (range 6,3–10,5 mmol/L) was documented in 12 neonates with type II 
antenatal Bartter syndrome and ventricular tachycardia has complicated the clinical 
course in one of them [44, 45].
5. Treatment
Biochemical confirmation should not delay treatment initiation in acutely 
sick infants. Infants with a severe salt-wasting present in near-shock to shock and 
require immediate fluid resuscitation and correction of electrolyte abnormalities. 
Physicians should keep in mind that a blood sample for the essential hormonal 
investigations should be collected before any steroid treatment is given to confirm 
aldosterone insufficiency and to determine the underlying cause. [7, 14, 46]
Hyponatremia is usually long-standing and should be corrected slowly to prevent 
central pontine myelinolysis [47]. Resolution of hyperkalemia usually occurs rapidly 
with stress doses of hydrocortisone, due to mineralocorticoid effect. Still, when 
T-wave elevation is evident on electrocardiogram (ECG), 10% calcium gluconate can 
be used to stabilize membrane potential. Other specific treatments for hyperkalemia 
include nebulized salbutamol and intravenous insulin infusion at 1 U of insulin 
in 5 g dextrose to promote intracellular potassium shifting and kayexalate cation 
exchange resins to help rid the potassium burden. As a last resort, dialysis can cor-
rect hyperkalemia, if T-wave elevation is unrelieved by medical means [10, 16, 47].
Infants with life-threatening salt-wasting crisis are initially treated with paren-
teral hydrocortisone at stress doses (50–100 mg/m2 per day divided q 8 h) pending 
steroid hormone analysis [48]. This approach is not unreasonable given that CAH is 
a potentially lethal condition if treatment is delayed. Stress doses of hydrocortisone 
also have adequate mineralocorticoid activity, as 20 mg of intravenous hydrocorti-
sone is equivalent to 100 μg fludrocortisone [10]. Once the infant is stabilized, he or 
she may be transitioned to oral hydrocortisone and fludrocortisone acetate at doses 
30 mg/m2 per day divided q 8 h and 50 to 100 μg/24 h respectively [49].
Identification of the etiology is crucial to avoid inappropriate prolonged steroid 
treatment, in case of mineralocorticoid resistance or isolated hypoaldosteronism. 
Appropriate therapy varies according to the etiology and treatment should be 
adjusted when the results are available [50].
a. In case of hypocortisolism glucocorticoid replacement therapy is continued 
according to established guidelines [7]. Maintenance therapy in infants with 
CAH includes hydrocortisone 12–15 mg/m2/d and oral fludrocortisone acetate 
(0.05 to 0.2 mg/24 h). The requirement for sodium in normally growing 
infants is ~1 mmol/kg per day, the amount provided by human milk. However, 
in infants with salt-wasting, this amount is insufficient and sodium chloride 
supplements are recommended at a dose of 1–2 g/d [51].
b. If appropriate cortisol levels are obtained, PAI is excluded and hydrocortisone 
can be discontinued. Serum aldosterone will further differentiate isolated 
hypoaldosteronism from PHA. In cases of isolated aldosterone deficiency 
therapy includes 9a-fludrocortisone and salt supplementation. However, 
infants with mineralocorticoid resistance will not respond to fludrocortisone 
treatment. Management of these cases is symptomatic with sodium repletion, 
ion - exchange resins and treatment of the precipitating cause (e.g. antibiotics 
for a urinary tract infection) [24].
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6. Causes of hypoaldosteronism
Hypoaldosteronism is classified in three large categories, according to their 
pathophysiology; deficient production by the adrenal glands, aldosterone 
unresponsiveness and defective stimulation of aldosterone secretion by renin 
(Table 1) [52].
The most common cause of aldosterone deficiency in the first weeks of life, is 
CAH due to 21-hydroxylase deficiency [38]. However, this diagnosis becomes less 
likely outside the neonatal period, by which time most cases have been diagnosed, 
either based on newborn screening or a salt-losing crisis. In boys, once CAH has 
been ruled out, the most common cause of hypoaldosteronism in early infancy 
(birth to 2 months) are the DAX-1 mutations, causing AHC. Other defects in aldo-
sterone biosynthesis include ASD, 3β-hydroxysteroid dehydrogenase deficiency, 
cholesterol side-chain cleavage enzyme deficiency and congenital lipoid hyperplasia 
due to deficiency of the steroidogenic acute regulatory (StAR) protein. PHA which 
results from diminished renal tubule responsiveness to aldosterone is another 
important cause of salt wasting in infancy [6]. Hyporeninemic hypoaldosteronism 
results in the same metabolic derangements, although this most often presents in 
adult populations. While rare in infants, the administration of nephrotoxic medica-
tions (e.g., ACE inhibitors, nonsteroidal anti-inflammatory drugs) should also be 
considered [30].
6.1  Deficient aldosterone production by the adrenal glands: hyperreninemic 
hypoaldosteronism
Where the primary defect is in aldosterone synthesis or release, the serum 
aldosterone concentration is low with a compensatory increase in PRA. Genetic 
defects in aldosterone biosynthesis, adrenal destruction and adrenal dysgenesis 
are the most common reported causes of hyperreninemic hypoaldosteronism 
[29, 53, 54].
Α. Defective production by the adrenal glands: Hyperreninemic hypoaldosteronism (↓ aldosterone - ↑ renin)
Combined with cortisol insufficiency Isolated hypoaldosteronism






Acquired disorders Autoimmune adrenalitis
Infections
Intra-adrenal hemorrhage
Drugs: Heparin, ACE inhibitors, 
ARBs
Β. Aldosterone resistance: Pseudohypoaldosteronism (↑ aldosterone - ↑ renin)
Primary, due to an inherited receptor defect
Secondary (UTI, urinary malformation, drugs)
C. Defective stimulation by renin: Hyporeninemic hypoaldosteronism (↓ aldosterone - ↓ renin)
In children with lupus nephritis, post-infectious glomerulonephritis or mild-to-moderate chronic renal 
insufficiency
Drugs: NSAIDs, COX-2 inhibitors, beta-blockers
Table 1. 
Causes of Hypoaldosteronism (CAH: congenital adrenal hyperplasia, ACE: angiotensin-converting enzyme, 
ARBs: angiotensin II receptor blockers, UTI: urinary tract infection, NSAIDs: nonsteroidal anti-inflammatory 
drugs, COX-2: cyclooxygenase-2).
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6.1.1 Salt-wasting forms of congenital adrenal hyperplasia
CAH is a group of autosomal recessive disorders characterized by cortisol insuf-
ficiency due to mutations affecting any of the steroidogenic enzymes required for cor-
tisol synthesis [51]. About 95% of CAH is caused by 21-hydroxylase deficiency, with 
the aldosterone-deficient form of the disease occurring in approximately 1:20.000 
births. Similarly, deficiencies of 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2), 
steroidogenic acute regulatory protein (StAR) and cholesterol side-chain cleavage 
enzyme (P450scc) inhibit both cortisol and aldosterone synthesis resulting in adrenal 
insufficiency with salt loss. Ambiguity of the genitalia in seen in 46,XX with 21OHD 
and 46,XY with 3βHSD2 deficiency. Paradoxically, 46,XX individuals born with 
severe 3βHSD2 deficiency can virilize slightly in utero, due to extra-adrenal 3βHSD1 
activity. Infants with lipoid CAH (StAR deficiency) have 46,XY sex reversal and 
normal-appearing female genitalia secondary to a severe defect in Leydig cell ste-
roidogenesis [1, 55]. A detailed review of this topic is beyond the scope of this chapter.
6.1.2 Aldosterone synthase deficiency
ASD is a rare case of hyperreninemic hypoaldosteronism inherited in an autoso-
mal recessive pattern and caused by mutations in the CYP11B2 gene encoding the 
enzyme aldosterone synthase [10, 56]. The CYP11B2 gene is located on chromosome 
8q22p, band q24.3, approximately 40 kb away from the 93% - identical CYP11B1 gene 
encoding the 11 β-hydroxylase enzyme [57]. Aldosterone synthase catalyzes the three 
final steps of aldosterone biosynthesis: first the 11-hydroxylation of deoxycorticoste-
rone (DOC) to corticosterone (compound B), then the hydroxylation at position 18 to 
18-hydroxycorticosterone (18OHB) and lastly the oxidation at position 18 to aldoste-
rone. According to the relative levels of aldosterone and its precursors, ASD has been 
subdivided into type 1 and type 2. It is important to note that 11-hydroxylation of 
DOC is not impaired in either type of ASD because it is also catalyzed by the CYP11B1 
isoenzyme, resulting in accumulation of both compound B and DOC [48, 58, 59].
Type 1 ASD, previously known as corticosterone methyloxidase I (CMO I) 
deficiency is typically characterized by total suppression of aldosterone synthase 
activity, resulting in impairment of both 18- hydroxylation and 18-oxidation. Thus, 
patients with ASD 1 have low to normal levels of 18OHB and very low to undetect-
able levels of aldosterone [58].
Type 2 ASD (CMO II deficiency) results from mutations in CYP11B2 gene that 
selectively affect the 18-methyl oxidase activity while preserving the 18- hydrox-
ylation of corticosterone, resulting in excessive levels of 18OHB and low to normal 
levels of aldosterone. Determination of 18OHB-to-aldosterone ratio enables recog-
nition of the site of the enzyme block [10, 19, 60, 61]. Type II ASD is characterized 
by a markedly (often 100-fold) elevated ratio in either urine or serum [62].
Despite their different biochemical profile, type 1 and type 2 ASD would be 
better considered a continuous spectrum of the same disease. 18-OHB exhibits 
minimal biological affinity for the MR and there is considerable overlap between 
the clinical, hormonal and genotypic features of the two types of the disease [6, 48]. 
The condition has manifestations ranging from life-threatening salt-wasting crisis 
in neonates to asymptomatic impairment of statural growth in children. The most 
common age of onset of major clinical salt wasting is between 1 week and three 
months of age [6, 58, 60]. Notably, impairment of linear growth may be the sole or 
the predominant feature in older children [6]. Although fatalities have occasionally 
occurred, the morbidity of ASD is usually not as severe as that of the salt-wasting 
forms of CAH, reflecting normal DOC, corticosterone and cortisol synthesis. 
Moreover, family studies have identified biochemically affected but asymptomatic 
adults with abnormal ratios of 18-oxygenated steroids [6, 62].
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ASD responds well to exogenous mineralocorticoid treatment. Infants will also 
require NaCl supplements for ongoing electrolyte management. Fludrocortisone 
doses do not need to be increased with age, since mineralocorticoid sensitivity 
increases throughout childhood [10, 63]. In the first months of life, fludrocorti-
sone’s recommended dosage is 0.05–0.3 mg/day. The dosage might be adjusted to 
about half of the initial dosage during the second year of life and a third or a quarter 
during the third year [64]. Mineralocorticoid replacement is typically continued 
throughout childhood, but is often gradually weaned by adolescence, as patients 
spontaneously ameliorate their salt-wasting syndrome. Normalization of serum 
electrolyte concentrations and suppression of PRA towards the normal age-adjusted 
range seem to represent reasonable objectives in children [6, 11, 63].
6.1.3  Familial hyperreninemic hypoaldosteronism unlinked to the aldosterone 
synthase (CYP11B2) gene
Isolated hyperreninemic hypoaldosteronism in infancy is usually caused by 
mutations in CYP11B2 gene. However, there have been several reports of infants 
with the same clinical picture, in whom no mutations of CYP11B2 were detected. 
An inherited form of hyperreninemic hypoaldosteronism, distinct from ASD, seems 
to be the cause and the affected gene(s) remain to be determined [57, 62].
6.1.4 Adrenal hypoplasia congenita
AHC is a rare inherited disorder of adrenal cortex development. It occurs in 2 
distinct forms: The X-linked cytomegalic form and the autosomal recessive minia-
ture adult form. In the X-linked or cytomegalic form, the adrenals do not differenti-
ate beyond the fetal stage. They are characterized by an absence of the permanent 
zone and by abnormally large (cytomegalic) cells. The autosomal recessive or 
miniature adult form is characterized by small adrenal glands with normal architec-
ture and normal adult zone structure [65–69].
X-linked AHC is caused by a defective NR0B1 (nuclear receptor subfamily 0, 
group B, member 1) gene [70]. About two thirds of boys with AHC have point 
mutations and the other one third has gene deletions [71]. The NR0B1 gene encodes 
the DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia, critical region on the X 
chromosome, gene 1) protein on the X-chromosome (Xp21) [69, 72, 73]. DAX-1 is an 
orphan nuclear receptor expressed in the adrenal cortex, testicular Leydig and Sertoli 
cells, ovarian theca and granulosa cells, pituitary gonadotropes and hypothalamus 
[70, 74]. Its actions are mediated by repression of another orphan nuclear receptor, 
steroidogenic factor 1 (SF-1) and together they regulate the embryological develop-
ment and subsequent function of these tissues. The prevalence of NR0B1 mutations 
in the general population has been estimated as 1:70,000–1:600,000 [69, 70, 72–77].
The classic form of X-linked AHC is characterized by three main features: 
primary adrenal failure, hypogonadotropic hypogonadism (HHG) and infertility 
[10]. A family history of adrenal failure, unexpected death or HHG, in males in the 
maternal family is evident in almost 100% of affected individuals [77]. The gold 
standard for diagnosis of X-linked AHC is genetic testing, showing a deletion or 
mutation in the NR0B1 (DAX1) gene [69].
6.1.4.1 Primary adrenal failure in X-linked AHC
Classically, a bimodal presentation pattern is seen, with 60% of affected 
males presenting during the first eight weeks of life and 40% presenting between 
1 to 10 years of age with primary adrenal failure or isolated mineralocorticoid 
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deficiency [76, 78]. The initial presentation of X-linked AHC is often a combination 
of mineral and glucocorticoid deficiency but, especially during the neonatal period, 
aldosterone deficiency may precede cortisol deficiency at onset [72]. An adult-
onset form of X-linked AHC has also been described in 10 males and diagnosis was 
suspected observing the association of adrenal insufficiency and hypogonadotropic 
hypogonadism. Variability in the age of onset is evident even among patients of the 
same family, carrying the same mutation, indicating that epigenetic or environ-
mental factors are also involved in the clinical course [67, 71, 72, 76, 77, 79].
Infants with PAI present with salt-wasting, failure to thrive, hyponatremia, 
hypoglycemia, and hyperpigmentation. Older individuals may present more insidi-
ously with chronic adrenal insufficiency until a concomitant illness precipitates 
acute adrenal crisis [71, 73].
A cortisol value within the normal range does not necessarily exclude the 
diagnosis of AHC and in several cases, children with normal basal cortisol levels 
presented with clinical adrenal failure shortly after. Glucocorticoid function should 
be carefully assessed, possibly through a short Synachten test, with sometimes an 
increase of ACTH level indicating compensated primary adrenal failure [57, 72, 78].
6.1.4.2 Hypogonadotropic hypogonadism in X-linked AHC
X-linked AHC is associated with isolated hypogonadotropic hypogonadism that 
seems to be the result of both hypothalamic and pituitary dysfunction. The deficit in 
pituitary hormones is selective for gonadotropins as other hormones’ production is 
normal. HHG usually becomes apparent in adolescence by absent or arrested puber-
tal development. Progression of puberty beyond Tanner III is extremely uncommon 
[65, 73, 76, 78, 80, 81].
Cryptorchidism may be present at birth, with at least 10% of infants having 
unilateral or more frequently bilateral undescended testes [76]. Against expecta-
tion, normal minipuberty of infancy with appropriately elevated gonadotropin and 
testosterone levels has been shown in 2 infants. The maternal uncles sharing the 
same DAX1 mutation with the infants, were affected by HHG [68, 82].
Other paradoxical features such as macrophallia or transient precocious sexual 
development have also been described in infancy and childhood, with several 
mechanisms proposed. Chronic excessive ACTH levels resulting from adrenal insuf-
ficiency may stimulate Leydig cells and lead to gonadotropin-independent preco-
cious puberty in some boys with DAX1 gene mutations [70, 83, 84].
6.1.4.3 Complex Glycerol Kinase Deficiency
Males with confirmed X- linked AHC should be evaluated for clinical signs of 
other diseases mapped in Xp21 because deletions of the NR0B1 gene may also occur 
along with contiguous gene defects as part of Complex Glycerol Kinase Deficiency 
(CGKD) [65, 69, 85]. CGKD develops from partial deletion of the Xp21 chromosomal 
locus involving all or part of the gene for glycerol kinase deficiency (GKD) together 
with that for AHC and/or Duchenne muscular dystrophy (DMD). Much larger 
deletions including the ornithine transcarbamylase locus have also been described 
[86–88]. The syndrome can be both sporadic and familial, and the phenotype varies 
according to the extension of deleted DNA [89]. Patients with CGKD may show 
dysmorphic features including prominent eyebrows and forehead and depressed 
nasal root giving the face an hourglass appearance [86]. Mental impairment is also 
described, but specific causes have not been clearly defined. The terminal 3′ end of 
the DMD gene is essential for normal development of the brain and a gene mapped 
distal to the DMD locus is associated with a form of X-linked mental retardation [89].
Renin-Angiotensin Aldosterone System
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6.2 Defective aldosterone action: pseudohypoaldosteronism (PHA)
Syndromes characterized by apparent aldosterone deficiency, despite elevated 
aldosterone levels are classified as PHA. This may be either primary (PHA type 1 
and 2) or secondary (PHA type 3) phenomenon. Primary PHA type 1 is subclas-
sified into two genetically distinct syndromes, that differ in the involvement of 
aldosterone target organs and the severity of salt wasting: (1) the autosomal domi-
nant (AD) or sporadic form (also called renal form) and (2) the autosomal recessive 
(AR) or generalized form. The biological characteristics of primary PHA1 and 
secondary PHA3 are dehydration accompanied by hyponatremia, hyperkalemia, 
and metabolic acidosis despite high aldosterone levels [27].
In contrast, type 2 PHA (Gordon syndrome or familial hyperkalemic hyper-
tension) is a rare potassium retaining syndrome characterized by hyperkalemia, 
normal GFR, hypertension, metabolic acidosis, suppressed PRA and variable 
aldosterone levels. It is caused by mutations affecting WNK1 and WNK4 kinases, as 
well as Cullin3 (CUL3) and Kelch-like3 (KLHL3) proteins. Comparison between the 
different types of PHA is presented in Table 2 [47, 91–93].
6.2.1 Multi-system PHA type 1
Multi-system PHA type 1 (sPHA) is characterized by multiple end-organ resis-
tance to aldosterone and is inherited as an autosomal recessive trait [94]. It is caused 
by homozygous or compound heterozygous inactivating mutations in the genes 
encoding the alpha, beta and gamma subunits of the ENaC. Both genes encoding 
the β- (SNCC1B) and γ-subunits (SNCC1G) are located in 16p12, while the gene 
encoding the α-subunit (SNCC1A) is located in 12p13 [71, 91, 95–97].
PHA sPHA type Ι rPHA type Ι PHA type ΙΙ PHA type ΙΙΙ
inheritance AR AD AD not inherited
mutated protein ENaC MR WNK1, WNK4, 
KLHL3, CUL3
none
patho-physiology salt loss  
K+ retention
salt loss  
K+ retention
salt and  
K+ retention
salt loss  
K+ retention




neonatal period  
early infancy
blood pressure hypotension hypotension hypertension hypotension






PRA ↑ ↑ ↓ ↑












duration persistent self-limited persistent transient
prognosis poor good good good
Table 2. 
Comparison Between the Different Types of PHA from references [47, 90] (PHA: pseudohypoaldosteronism; 
AR: autosomal recessive; AD: autosomal dominant; MR: mineralocorticoid receptor; ENaC: epithelial sodium 
channel; WNK: with-no-lysine (K) kinase; CUL3: Cullin3 and KLHL3: Kelch-like3).
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Since the ENaC is expressed in all aldosterone - dependent epithelial tissues 
(distal part of the nephron, distal colon, salivary ducts, sweat glands, respiratory 
airway, pulmonary alveoli and nasal mucosa), sPHA is associated with widespread 
systemic manifestations [91, 98]. The pattern of laboratory abnormalities is diag-
nostic and shows hyponatremia, hyperkalemia, metabolic acidosis, elevated PRA 
and aldosterone concentrations. The course of the disease is severe and lifelong 
treatment is required [92, 99].
In utero, uncontrolled saliuretic fetal polyuria due to mineralocorticoid resistance 
may lead to polyhydramnios. In the postnatal period, sPHA is characterized by 
failure to thrive, vomiting and severe dehydration. Affected infants may also have 
chronic diarrhea, excessive pulmonary secretions, cholelithiasis and recurrent skin 
rashes [99–101]. Other associated symptoms include chronic discharge of clear liquid 
from the nose and salt loss from the Meibomian glands of the eyelids [90, 93, 102].
Lower respiratory tract involvement associated with sPHA makes the disease 
an important mimic of cystic fibrosis. ENaC plays a major role in airway sodium 
absorption, airway liquid volume and composition [103]. First, the increased volume 
of intraluminal liquid results in airway narrowing. This is especially evident during 
infancy and early childhood, when the airway diameter is small. Besides, changes in 
the airways’ ionic composition may compromise normal mucociliary function, pre-
disposing to lower respiratory tract infections. However, children generally do not 
present after age 5 and do not typically develop Pseudomonas aeruginosa lung infec-
tions. These features differentiate children with sPHA from those with cystic fibrosis 
[94, 95, 103–105]. Infants with sPHA sustain recurrent episodes (3–6 per year) of 
chest congestion, coughing and tachypnea, often associated with fever, wheez-
ing and crackles. It is noteworthy, that respiratory symptoms begin within weeks 
or months after birth and only two newborns with neonatal respiratory distress 
syndrome (RDS) and sPHA have been described. Both were premature, one born at 
31 weeks of gestation and one born at 36 weeks. Older patients (more than five years 
of age) have less severe and less frequent respiratory symptoms [47, 90, 98].
Defective ENaC function is also responsible for the high sweat salt concentration 
of infants with sPHA, making the sweat test an excellent discriminant between the 
systemic and the renal type of the disease [92]. The high sodium concentration also 
causes chronic inflammatory changes around and within the sweat ducts resulting 
in recurrent skin rashes. Cutaneous manifestations of patients with sPHA1 mimic 
pustular miliaria rubra and are described as discrete erythematous pustules, that 
worsen during salt-depletion crises and clear spontaneously with stabilization. 
Interestingly, inflammatory pustules have not been noted in patients with cystic 
fibrosis. The reason for this is unknown, but may relate to higher sweat salt concen-
trations in sPHA. Typical sweat chloride concentrations in infants with sPHA range 
between 110 and 150 mmol/L. In comparison, sweat chloride concentrations higher 
than 75 mmol/L are reported in patients with cystic fibrosis [99, 102, 106].
Normalization of fluid and electrolyte balance in generalized PHA1 is particu-
larly challenging. Patients are insensitive to mineralocorticoids and require high 
doses of sodium supplementation (between 20 and 50 mEq/kg/d), together with 
orally administered ion exchange resins and dietary potassium restriction. Although 
a slight amelioration is observed with ageing, treatment is mandatory throughout 
life [102, 107].
6.2.2 Renal PHA type 1
Renal PHA type 1 (rPHA) is an autosomal dominant (AD) disease caused by 
heterozygous mutations in the NR3C2 gene. The NR3C2 gene located on chromo-
some 4q31.1 is responsible for encoding the the distal renal tubule’s mineralocorticoid 
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receptor [90, 91, 94]. More than 50 different mutations have been identified in this 
receptor, which lead to renal resistance to aldosterone [71]. The renal type of PHA 
represents the most frequent form of the disease with a prevalence of 1 per 80.000 
newborns [102].
AD-PHA is restricted to the kidneys and clinical symptoms usually remit with 
age. Although less severe in its course, rPHA has been reported to be associated with 
high infant mortality rate. In fact, patients with rPHA resemble a striking pheno-
typic diversity, with a clinical spectrum ranging from asymptomatic to severe PHA. 
Characteristic of the autosomal dominant form is an affected, symptomatic index 
case, with family members who are biochemically affected but clinically asymp-
tomatic. Sporadic cases due to de novo mutations have also been reported [90, 97, 
108–110].
Patients mainly manifest in early infancy, between 0.5 and 6 months of age, with 
isolated renal resistance to aldosterone, leading to renal salt loss, hyponatremia, 
hyperkalemia, metabolic acidosis, failure to thrive and elevated plasma renin and 
aldosterone concentrations. The main clinical symptom is failure to thrive due to 
chronic dehydration. Hyperkalemia is generally mild, and metabolic acidosis is not 
always detectable [93].
In rPHA, 3–20 mEq/kg/daily dose of sodium is sufficient to compensate for the 
salt loss and is followed by a rapid clinical and biochemical improvement [105]. 
Potassium-binding resins are rarely needed. Although the primary defect persists 
for life, improvement usually occurs after the first years of life and sodium supple-
mentation generally becomes unnecessary by 2–3 years of age. Amelioration of 
the phenotype is attributed to the renal tubule’s maturation, autonomous addition 
of salt to the diet and chronic up-regulation of mineralocorticoid axis. Chronic 
salt depletion and resultant hyperreninemia possibly stimulates zona glomerulosa 
leading to the zone’s hypertrophy and tertiary hyperaldosteronism. Thus, PRA 
decreases into normal range, while high plasma aldosterone levels persist into 
 adulthood [90, 102, 105, 108].
6.2.3 Secondary PHA type 3
Secondary PHA in infancy is a transient condition characterized by lack of 
response to aldosterone in the distal tubule due to obstructive uropathy, VUR and/
or UTI [111]. Any kind of urinary tract obstruction, including posterior urethral 
valves, ureterocele, ureteropelvic junction obstruction and ureterohydronephrosis 
may lead to PHA [106, 109].
The underlying pathogenesis for secondary aldosterone resistance has not 
been fully elucidated. Early infancy, however, seems to be the main contributing 
factor, as the prevalence rate of secondary PHA diminishes considerably after 
three months of age, with the majority of infants being less than seven months 
old [106, 110, 112].
Inflammation and production of cytokines is an additional factor contributing 
to aldosterone resistance. Circulating bacterial endotoxins can directly damage 
aldosterone receptors, as well as stimulate the intrarenal synthesis of cytokines 
like prostaglandins, leukotriens, endothelin, interleukin (IL)-1 and thromboxane. 
Similarily, parenchymal renal damage in case of obstructive uropathy increases the 
intrarenal expression of tumor necrosis factor-alpha (TNF-α), IL-1, IL-6, trans-
forming growth factor beta-1 (TGF-β1), angiotensin II, endothelin, thromboxane 
A2 and prostaglandins. These cytokines induce vasoconstriction, reduction of GFR, 
natriuresis and/or decreased Na+-K+-ATPase activity [90, 111].
Secondary PHA is typically an acute condition. Electrolyte imbalance usually 
resolves after 24–48 hours of intravenous fluid replacement and antibiotic therapy 
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in the case of UTI [113]. However, signs of pseudohypoaldosteronism have been 
reported to persist even after successful surgery in infants with congenital hydro-
nephrosis, indicative of ongoing distal tubular dysfunction. The required time 
period for salt supplementation ranges from 3 to 13 months in reported cases, with 
the youngest infants requiring longer supplementation [25, 106]. If secondary PHA 
improves with treatment of UTI or obstructive uropathy, further genetic testing 
for primary PHA1 is not usually suggested [114]. Interestingly, a pathogenic muta-
tion on NR3C2 has been recently identified in an infant with UTI-associated type 
IV renal tubular acidosis (RTA). Identification of MR or epithelial sodium channel 
(ENaC) gene polymorphisms in the presence of secondary PHA is suggestive of a 
possible overlap between primary and secondary type IV RTA [106, 115].
6.3 Defective stimulation by renin: hyporeninemic hypoaldosteronism
Hyporeninemic hypoaldosteronism results from insufficient stimulation of the 
adrenal gland due to a defect of renin secretion. The syndrome has been especially 
observed in adults with chronic renal insufficiency due to diabetic nephropathy and 
rarely in children with lupus nephritis or acute post-infectious glomerulonephritis 
[15, 116].
Only five infants with hyporeninemic hypoaldosteronism have been reported 
to date. An 8-month-old boy with chronic kidney disease (CKD) stage 3 caused 
by tubulointerstitial disease manifested hyperkalemia (potassium = 7.1 mEq/L) 
with normal GFR in the context of hyporeninemic hypoaldosteronism [117]. 
Hyporeninemic hypoaldosteronism has also been reported in a 3-month-old boy 
with severe psychomotor retardation and growth failure and a 5-month-old boy 
with severe mental retardation lactic acidosis and deafness [116]. Finally, the report 
of two male siblings, presenting with hyporeninemic hypoaldosteronism at the age 
of 12 and 2 months suggested a congenital primary defect [118].
7. Conclusions
Although rare, hypoaldosteronism is a potential cause of neonatal morbidity 
and mortality due to electrolyte disturbances and hypovolemia. Early diagnosis and 
treatment represent a major challenge for pediatricians, who should be aware of this 
condition either as isolated hypoaldosteronism or in the context of PAI. A deeper 
understanding of the etiology of hypoaldosteronism is crucial, to improve care of 
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